CAM
ENTA icon

Cormorant Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Cormorant Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,000
Closed -$273K – 48
2013
Q4 		$273K Buy
+10,000
New +$242K 0.08% 37

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
ICRM
Insight Capital Research & Management Walnut Creek, California $177M AUM 72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return

Cormorant Asset Management's ENTA Position: Q1 2014 in Review

Cormorant Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2014, closing a stake of 10,000 shares — an estimated $273K sold.

Cormorant Asset Management first reported a position in ENTA in Q4 2013 and held it in 1 quarter. The position peaked at $273K in Q4 2013. 81 funds tracked by Wall St. Rank hold ENTA as of Q1 2014.

  • Cormorant Asset Management reported no remaining Enanta Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Cormorant Asset Management sold 10,000 Enanta Pharmaceuticals shares in Q1 2014, an estimated $273K.
  • Cormorant Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Cormorant Asset Management's Enanta Pharmaceuticals position peaked at $273K in Q4 2013.
  • 81 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2014.

Based on Cormorant Asset Management's 13F filing for Q1 2014, filed 15 May 2014.